BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 38406391)

  • 1. A Prospective Study Assessing the Efficacy and Toxicity of Stereotactic Body Radiation Therapy for Oligometastatic Bone Metastases.
    Lee JH; Shi DD; Shin KY; Buckley E; Gunasti L; Hall E; Mann E; Spicer B; Chen YH; Hammoudeh L; Brennan V; Huynh MA; Spektor A; Krishnan MS; Balboni TA; Hertan LM
    Adv Radiat Oncol; 2024 Apr; 9(4):101411. PubMed ID: 38406391
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stereotactic Body Radiation Therapy for Oligometastatic Prostate Cancer.
    Muldermans JL; Romak LB; Kwon ED; Park SS; Olivier KR
    Int J Radiat Oncol Biol Phys; 2016 Jun; 95(2):696-702. PubMed ID: 27131082
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcomes and toxicities of stereotactic body radiation therapy for non-spine bone oligometastases.
    Owen D; Laack NN; Mayo CS; Garces YI; Park SS; Bauer HJ; Nelson K; Miller RW; Brown PD; Olivier KR
    Pract Radiat Oncol; 2014; 4(2):e143-e149. PubMed ID: 24890360
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stereotactic Body Radiotherapy for Recurrent or Oligometastatic Uterine Cervix Cancer: A Cooperative Study of the Korean Radiation Oncology Group (KROG 14-11).
    Park HJ; Chang AR; Seo Y; Cho CK; Jang WI; Kim MS; Choi C
    Anticancer Res; 2015 Sep; 35(9):5103-10. PubMed ID: 26254414
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ablative dose stereotactic body radiation therapy for oligometastatic disease: a prospective single institution study.
    Burkon P; Kazda T; Pospisil P; Slavik M; Kominek L; Selingerova I; Blakaj DM; Prochazka T; Vrzal M; Rehak Z; Slampa P
    Neoplasma; 2019 Mar; 66(2):315-325. PubMed ID: 30509112
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Large, Multicenter, Retrospective Study on Efficacy and Safety of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Ovarian Cancer (MITO RT1 Study): A Collaboration of MITO, AIRO GYN, and MaNGO Groups.
    Macchia G; Lazzari R; Colombo N; Laliscia C; Capelli G; D'Agostino GR; Deodato F; Maranzano E; Ippolito E; Ronchi S; Paiar F; Scorsetti M; Cilla S; Ingargiola R; Huscher A; Cerrotta AM; Fodor A; Vicenzi L; Russo D; Borghesi S; Perrucci E; Pignata S; Aristei C; Morganti AG; Scambia G; Valentini V; Jereczek-Fossa BA; Ferrandina G
    Oncologist; 2020 Feb; 25(2):e311-e320. PubMed ID: 32043791
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Outcomes Among Patients Treated With Stereotactic Body Radiation Therapy to Femur Metastases for Oligometastatic Disease Control or Reirradiation: Results From a Large Single-Institution Experience.
    Kwan C; Chen YH; Killoran JH; Ferrone M; Marcus KJ; Tanguturi S; Balboni TA; Spektor A; Huynh MA
    Adv Radiat Oncol; 2024 Apr; 9(4):101439. PubMed ID: 38419821
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stereotactic Body Radiation Therapy (SBRT) for Oligorecurrent/Oligoprogressive Mediastinal and Hilar Lymph Node Metastasis: A Systematic Review.
    Cozzi S; Alì E; Bardoscia L; Najafi M; Botti A; Blandino G; Giaccherini L; Ruggieri MP; Augugliaro M; Iori F; Sardaro A; Iotti C; Ciammella P
    Cancers (Basel); 2022 May; 14(11):. PubMed ID: 35681659
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stereotactic Body Radiation Therapy: A Versatile, Well-Tolerated, and Effective Treatment Option for Extracranial Metastases From Primary Ovarian and Uterine Cancer.
    Aghdam N; Repka MC; McGunigal M; Pepin A; Paydar I; Rudra S; Paudel N; Pernia Marin M; Suy S; Collins SP; Barnes W; Collins BT
    Front Oncol; 2020; 10():572564. PubMed ID: 33425723
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Detected via Prostate-specific Membrane Antigen Positron Emission Tomography.
    Kneebone A; Hruby G; Ainsworth H; Byrne K; Brown C; Guo L; Guminski A; Eade T
    Eur Urol Oncol; 2018 Dec; 1(6):531-537. PubMed ID: 31158100
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Single-institutional outcome-analysis of low-dose stereotactic body radiation therapy (SBRT) of adrenal gland metastases.
    Voglhuber T; Kessel KA; Oechsner M; Vogel MME; Gschwend JE; Combs SE
    BMC Cancer; 2020 Jun; 20(1):536. PubMed ID: 32513136
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of stereotactic body radiotherapy to primary tumor and metastatic locations in oligometastatic nonsmall-cell lung cancer patients.
    Collen C; Christian N; Schallier D; Meysman M; Duchateau M; Storme G; De Ridder M
    Ann Oncol; 2014 Oct; 25(10):1954-1959. PubMed ID: 25114022
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stereotactic Body Radiation Therapy for Oligometastatic Breast Cancer: A Retrospective Multicenter Study.
    Lemoine P; Bruand M; Kammerer E; Bogart E; Comte P; Royer P; Thariat J; Pasquier D
    Front Oncol; 2021; 11():736690. PubMed ID: 34778049
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stereotactic body radiotherapy (SBRT) versus androgen deprivation therapy (ADT) for oligometastatic prostate cancer: protocol for a prospective randomised control clinical trial.
    Zhao X; Wang T; Ye Y; Li J; Gao X; Zhang H
    BMJ Open; 2022 Sep; 12(9):e051371. PubMed ID: 36180115
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I/II Study of Extreme Hypofractionated Stereotactic Body Radiation Therapy Boost to Prostate for Locally Advanced, Node-Positive and Oligometastatic Cancer.
    Narang K; Kadian M; Venkatesan K; Mishra S; Bisht S; Gupta D; Banerjee S; Kataria T
    Cureus; 2020 Nov; 12(11):e11751. PubMed ID: 33403181
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase 2 Study of Stereotactic Body Radiation Therapy for Patients with Oligometastatic Esophageal Squamous Cell Carcinoma.
    Liu Q; Zhu Z; Chen Y; Deng J; Ai D; Liu Q; Wang S; Wu S; Chen J; Zhao K
    Int J Radiat Oncol Biol Phys; 2020 Nov; 108(3):707-715. PubMed ID: 32417405
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ten-Year Outcomes of Stereotactic Body Radiotherapy for Oligometastatic Breast Cancer: Does Synchronous Oligometastatic Breast Cancer Benefit?
    Nagpal SK; Khabra K; Ross G; Kirby AM
    Clin Oncol (R Coll Radiol); 2023 Nov; 35(11):736-743. PubMed ID: 37684189
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stereotactic Body Radiation Therapy for Oligometastatic Ovarian Cancer: A Step Toward a Drug Holiday.
    Lazzari R; Ronchi S; Gandini S; Surgo A; Volpe S; Piperno G; Comi S; Pansini F; Fodor C; Orecchia R; Tomao F; Parma G; Colombo N; Jereczek-Fossa BA
    Int J Radiat Oncol Biol Phys; 2018 Jul; 101(3):650-660. PubMed ID: 29893277
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stereotactic body radiotherapy for the treatment of oligometastatic gynecological malignancy in the abdomen and pelvis: A single-institution experience.
    Smile TD; Reddy CA; Qiao-Guan G; Winter WI; Stephans KL; Woody NM; Balagamwala EH; Amarnath SR; Magnelli A; AlHilli MM; Michener CM; Mahdi H; DeBernardo RL; Rose PG; Cherian SS
    J Radiosurg SBRT; 2021; 7(3):189-197. PubMed ID: 33898082
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I Trial of Stereotactic Body Radiation Therapy Dose Escalation in Pancreatic Cancer.
    Courtney PT; Paravati AJ; Atwood TF; Raja N; Zimmerman CT; Fanta PT; Lowy AM; Simpson DR; Xu R; Murphy JD
    Int J Radiat Oncol Biol Phys; 2021 Jul; 110(4):1003-1012. PubMed ID: 33571625
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.